

TETRAPHASE PHARMACEUTICALS INC

Form S-8

March 18, 2019

As filed with the Securities and Exchange Commission on March 18, 2019

Registration No. 333-

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM S-8**  
**REGISTRATION STATEMENT**  
***UNDER***  
***THE SECURITIES ACT OF 1933***

**Tetraphase Pharmaceuticals, Inc.**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**480 Arsenal Way**

**20-5276217**  
**(I.R.S. Employer**

**Identification No.)**

**02472**

**Watertown, MA**  
**(Address of Principal Executive Offices)** **(Zip Code)**  
**2013 Stock Incentive Plan**

**Inducement Stock Option Awards**

**(Full title of the plans)**

**Maria Stahl**

**Senior Vice President and General Counsel**

**480 Arsenal Way**

**Watertown, MA 02472**

**(Name and address of agent for service)**

**(617) 715-3600**

**(Telephone number, including area code, of agent for service)**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

### CALCULATION OF REGISTRATION FEE

<b>Title of securities to be registered</b>	<b>Amount to be registered(1)</b>	<b>Proposed maximum offering price per share</b>	<b>Proposed maximum aggregate offering price</b>	<b>Amount of registration fee</b>
Common Stock, \$0.001 par value per share	2,147,192 shares (2)	\$1.23 (3)	\$2,641,046 (3)	\$320
Common Stock, \$0.001 par value per share	248,250 shares (4)	\$3.08 (5)	\$764,610 (5)	\$93

- (1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, reverse stock splits, stock dividends, recapitalizations or similar transactions.
- (2) Represents additional shares of Common Stock authorized for issuance under the 2013 Stock Incentive Plan.
- (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of \$1.23, the average of the high and low prices of the registrant's Common Stock as reported on the Nasdaq Global Market on March 12, 2019.
- (4) Consists of an aggregate of 248,250 shares of Common Stock issuable pursuant to award agreements to 40 employees of the registrant, issued as an inducement material to entry into employment with the registrant in accordance with Nasdaq Listing Rule 5635(c)(4), or the Inducement Awards.
- (5) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act of 1933, as amended. The price per share represents the weighted average of the exercise prices for outstanding options under the Inducement Awards.

## **EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by Tetraphase Pharmaceuticals, Inc., a Delaware corporation, or the registrant, to register (a) 2,147,192 shares of the registrant's common stock, \$0.001 par value per share, or Common Stock, issuable under the registrant's 2013 Stock Incentive Plan, or the 2013 Plan, and (b) an aggregate of 248,250 shares of Common Stock issuable upon exercise of non-qualified stock options granted to 40 employees of the registrant (options to purchase an aggregate of 60,000 shares granted on June 15, 2018, options to purchase an aggregate of 60,000 shares granted on July 13, 2018 and options to purchase an aggregate of 128,250 shares granted on October 15, 2018), as an inducement material to entry into employment with the registrant, in accordance with Nasdaq Listing Rule 5635(c)(4). Pursuant to General Instruction E to Form S-8, and only with respect to the Common Stock being registered under the 2013 Plan, except as otherwise set forth below, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8 filed by the registrant on June 14, 2013 (File No. 333-189361) relating to the 2013 Plan.

### **PART I**

#### **INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended, or the Securities Act, and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission, or the Commission, and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.

### **PART II**

#### **INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

##### **Item 3. Incorporation of Documents by Reference.**

The registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance therewith files reports, proxy statements and other information with the Commission. The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

- (a) The registrant's latest annual report filed pursuant to Section 13(a) or 15(d) of the Exchange Act or the latest prospectus filed pursuant to Rule 424(b) under the Securities Act that contains audited financial statements for the registrant's latest fiscal year for which such statements have been filed.
- (b) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the document referred to in (a) above.
- (c) The description of the securities contained in the registrant's Registration Statement on Form 8-A filed under the Exchange Act, including any amendment or report filed for the purpose of updating such description.

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form S-8

All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The registrant's certificate of incorporation provides that none of its directors shall be personally liable to the registrant or its stockholders for monetary damages for any breach of fiduciary duty as director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

The registrant's certificate of incorporation provides that the registrant will indemnify each person who was or is a party or threatened to be made a party to or is involved in any threatened, pending or completed action, suit or proceeding by reason of the fact that he or she is or was a director or officer of the registrant, or is or was serving at the registrant's request as a director or officer of another corporation, partnership, joint venture, trust or other enterprise to the fullest extent permitted by the Delaware General Corporation Law. The registrant's certificate of incorporation provides that expenses must be advanced to these indemnitees under certain circumstances.

The indemnification provisions contained in the registrant's certificate of incorporation are not exclusive. In addition, the registrant has entered into indemnification agreements with each of its directors and executive officers. Each indemnification agreement provides that the registrant will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his capacity as a director or executive officer, provided that he acted in good faith and in a manner that he reasonably believed to be in, or not opposed to, the registrant's best interests and, with respect to any criminal proceeding, had no reasonable cause to believe that his conduct was unlawful. In the event that the registrant does not assume the defense of a claim against a director or executive officer, the registrant is required to advance his expenses in connection with his defense, provided that he undertakes to repay all amounts advanced if it is ultimately determined that he is not entitled to be indemnified by the registrant.

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form S-8

In addition, the registrant maintains standard policies of insurance under which coverage is provided to the registrant's directors and officers against losses arising from claims made by reason of breach of duty or other wrongful act, and to the registrant with respect to payments which may be made by the registrant to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

**INDEX TO EXHIBITS**

Number	Description
4.1	<u>Restated Certificate of Incorporation of the registrant (filed as Exhibit 3.1 to the registrant's Quarterly Report on Form 10-Q (File No. 001-35837) filed with the Securities and Exchange Commission on May 13, 2013 and incorporated by reference herein)</u>
4.2	<u>Amended and Restated By-Laws of the registrant (filed as Exhibit 3.2 to the registrant's Quarterly Report on Form 10-Q (File No. 001-35837) filed with the Securities and Exchange Commission on May 13, 2013 and incorporated by reference herein)</u>
5	<u>Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the registrant</u>
23.1	<u>Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5)</u>
23.2	<u>Consent of Ernst &amp; Young LLP</u>
24	<u>Power of attorney (included on the signature pages of this registration statement)</u>
99.1	<u>Non-Qualified Stock Option Inducement Award Agreement (filed as Exhibit 10.3 to the registrant's Quarterly Report on Form 10-Q (File No. 001-35837) filed with the Securities and Exchange Commission on May 7, 2015 and incorporated by reference herein)</u>
99.2	<u>2013 Stock Incentive Plan (filed as Exhibit 10.8 to the registrant's Registration Statement on Form S-1 (File No. 333-186574) filed with the Securities and Exchange Commission on March 5, 2013 and incorporated by reference herein)</u>

**Item 9. Undertakings.**

1. Item 512(a) of Regulation S-K. The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

*provided, however*, that paragraphs (i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the



Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form S-8

registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

2. Item 512(b) of Regulation S-K. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

3. Item 512(h) of Regulation S-K. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Watertown, Commonwealth of Massachusetts, on this 18th day of March, 2019.

TETRAPHASE  
PHARMACEUTICALS, INC.

By: /s/ Guy Macdonald  
Guy Macdonald

President and Chief Executive  
Officer

## POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Tetrphase Pharmaceuticals, Inc., hereby severally constitute and appoint Guy Macdonald, Maria Stahl and Christopher Watt, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Tetrphase Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Guy Macdonald Guy Macdonald	President and Chief Executive Officer, Director (Principal Executive Officer)	March 18, 2019
/s/ Christopher Watt Christopher Watt	Senior Vice President, Finance (Principal Financial Officer and Principal Accounting Officer)	March 18, 2019
/s/ L. Patrick Gage L. Patrick Gage	Director	March 18, 2019
/s/ Garen Bohlin	Director	March 18, 2019

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form S-8

Garen Bohlin

/s/ Jeffrey Chodakewitz	Director	March 18, 2019
-------------------------	----------	----------------

Jeffrey Chodakewitz

/s/ John G. Freund	Director	March 18, 2019
--------------------	----------	----------------

John G. Freund

/s/ Geraldine Henwood	Director	March 18, 2019
-----------------------	----------	----------------

Geraldine Henwood

/s/ Nancy Wysenski	Director	March 18, 2019
--------------------	----------	----------------

Nancy Wysenski